Go to
JCI Insight
Citations to this article
Abstract
Authors
Saul J. Farber, Eugene Y. Berger, David P. Earle
Total citations by year
Citation information
Citations to this article (144)
| Title and authors | Publication | Year |
|---|---|---|
|
Handling the sugar rush: the role of the renal proximal tubule
Spellman MJ 3rd, Assaf T, Nangia S, Fernandez J, Nicholson KC, Shepard BD |
American Journal of Physiology - Renal Physiology | 2024 |
|
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials.
Ji L, Mishra M, De Geest B |
Pharmaceutics | 2023 |
|
Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis.
Pozzi A, Cirelli C, Merlo A, Rea F, Scangiuzzi C, Tavano E, Iorio A, Kristensen SL, Wong C, Iacovoni A, Corrado G |
Heart Failure Reviews | 2023 |
|
The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Oe Y, Vallon V |
2022 | |
|
Role of Insulin in Health and Disease: An Update
S Rahman, KS Hossain, S Das, S Kundu, EO Adegoke, A Rahman, A Hannan, J Uddin, MG Pang |
International journal of molecular sciences | 2021 |
|
Diabetes and Cardiovascular Risk in Renal Transplant Patients
J Rysz, B Franczyk, M Radek, A Ciałkowska-Rysz, A Gluba-Brzózka |
International journal of molecular sciences | 2021 |
|
Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences
GD GIUSEPPE, G CICCARELLI, CM CEFALO, F CINTI, S MOFFA, F IMPRONTA, U CAPECE, A PONTECORVI, A GIACCARI, T MEZZA |
Minerva endocrinology | 2021 |
|
Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge
M Provenzano, MC Pelle, I Zaffina, B Tassone, R Pujia, M Ricchio, R Serra, A Sciacqua, A Michael, M Andreucci, F Arturi |
Frontiers in Medicine | 2021 |
|
Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
N Srinivas, MK Sarnaik, S Modi, Y Pisipati, S Vaidya, NS Gaggatur, AH Sange, I Sange |
Cureus | 2021 |
|
Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease
S Ravindran, S Munusamy |
Journal of Cellular Physiology | 2021 |
|
Renal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon V, Nakagawa T |
Comprehensive Physiology | 2021 |
|
The tubular hypothesis of nephron filtration and diabetic kidney disease
V Vallon, SC Thomson |
Nature Reviews Nephrology | 2020 |
|
Glucose transporters in the kidney in health and disease
V Vallon |
Pflügers Archiv - European Journal of Physiology | 2020 |
|
The use of sodium‐glucose co‐transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?
T Koufakis, OG Mustafa, RA Ajjan, X GarciaMoll, P Zebekakis, G Dimitriadis, K Kotsa |
Journal of Clinical Pharmacy and Therapeutics | 2020 |
|
Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
E Ferrannini, R Pereira-Moreira, M Seghieri, E Rebelos, AL Souza, VB Chueire, C Arvia, E Muscelli |
BMJ Open Diabetes Research & Care | 2020 |
|
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
MR Cowie, M Fisher |
Nature Reviews Cardiology | 2020 |
|
Effect of Insulin on Proximal Tubules Handling of Glucose: A Systematic Review
R Pereira-Moreira, E Muscelli |
Journal of Diabetes Research | 2020 |
|
SGLT inhibitors as antidiabetic agents: a comprehensive review
Kshirsagar RP, Kulkarni AA, Chouthe RS, Pathan SK, Une HD, Reddy GB, Diwan PV, Ansari SA, Sangshetti JN |
RSC Advances | 2020 |
|
Insulin: Trigger and Target of Renal Functions
AF Pina, DO Borges, MJ Meneses, P Branco, R Birne, A Vilasi, MP Macedo |
Frontiers in Cell and Developmental Biology | 2020 |
|
Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development
E Gronda, M Jessup, M Iacoviello, A Palazzuoli, C Napoli |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | 2020 |
|
Ominous Octet and Other Scary Diabetes Stories
SD Kelly, SL Neary |
Physician Assistant Clinics | 2020 |
|
Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
AP McGovern, M Hogg, BM Shields, NA Sattar, RR Holman, ER Pearson, AT Hattersley, AG Jones, JM Dennis |
BMJ Open Diabetes Research & Care | 2020 |
|
SGLT inhibitors as antidiabetic agents: a comprehensive review
RP Kshirsagar, AA Kulkarni, RS Chouthe, SK Pathan, HD Une, GB Reddy, PV Diwan, SA Ansari, JN Sangshetti |
RSC Advances | 2020 |
|
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
B Liu, Y Wang, Y Zhang, B Yan |
Current topics in medicinal chemistry | 2019 |
|
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors
E Brown, SP Rajeev, DJ Cuthbertson, JP Wilding |
Diabetes, obesity & metabolism | 2019 |
|
Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
E Brown, JP Wilding, TM Barber, U Alam, DJ Cuthbertson |
Obesity reviews : an official journal of the International Association for the Study of Obesity | 2019 |
|
Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors
E Cersosimo, JM Miles |
Current diabetes reviews | 2019 |
|
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
A Tentolouris, P Vlachakis, E Tzeravini, I Eleftheriadou, N Tentolouris |
International journal of environmental research and public health | 2019 |
|
Ion Channels and Transporters in Diabetic Kidney Disease
Spires D, Manis AD, Staruschenko A |
Current topics in membranes | 2019 |
|
Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice YK Jiang, KY Xin, HW Ge, FJ Kong, G Zhao |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy | 2019 |
|
KIDNEY FUNCTION IN EXPERIMENTAL DIABETES
AY Zharikov, BA Balandovich, RO Shchekochikhina, GV Zharikova |
2019 | |
|
The Diabetes Textbook: Clinical Principles, Patient Management and Public Health Issues
J Rodriguez-Saldana |
2019 | |
|
Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
D Basu, LA Huggins, D Scerbo, J Obunike, AE Mullick, PL Rothenberg, NA Prospero, RH Eckel, IJ Goldberg |
Arteriosclerosis, thrombosis, and vascular biology | 2018 |
|
Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
E Bonora, R DeFronzo |
2018 | |
|
Effects of sodium glucose co-transporter 2 inhibitors on the kidney
N de Albuquerque Rocha, IJ Neeland, PA McCullough, RD Toto, DK McGuire |
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease | 2018 |
|
Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption
S Li, N Wang, X Guo, J Li, T Zhang, G Ren, D Li |
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie | 2018 |
|
Diabetes Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
E Bonora, RA DeFronzo |
2018 | |
|
Therapeutic medications against diabetes: What we have and what we expect
C Hu, W Jia |
Advanced Drug Delivery Reviews | 2018 |
|
Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential
ME Røder |
Therapeutic Advances in Chronic Disease | 2017 |
|
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes
H Al-Jobori, G Daniele, E Cersosimo, C Triplitt, R Mehta, L Norton, RA DeFronzo, M Abdul-Ghani |
Diabetes | 2017 |
|
Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement
S Kalra, S Ghosh, AH Aamir, MT Ahmed, MF Amin, S Bajaj, MP Baruah, U Bulugahapitiya, AK Das, M Giri, S Gunatilake, SA Mahar, MF Pathan, NK Qureshi, SA Raza, R Sahay, S Shakya, D Shreshta, N Somasundaram, M Sumanatilleke, AG Unnikrishnan, AM Wijesinghe |
Indian journal of endocrinology and metabolism | 2017 |
|
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE
XX Wang, J Levi, Y Luo, K Myakala, M Herman-Edelstein, L Qiu, D Wang, Y Peng, A Grenz, S Lucia, E Dobrinskikh, VD D'Agati, H Koepsell, JB Kopp, AZ Rosenberg, M Levi |
The Journal of biological chemistry | 2017 |
|
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
E Ferrannini |
Cell Metabolism | 2017 |
|
The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes
K Jaikumkao, A Pongchaidecha, V Chatsudthipong, SC Chattipakorn, N Chattipakorn, A Lungkaphin |
Biomedicine & Pharmacotherapy | 2017 |
|
Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia
A Szalat, A Perlman, M Muszkat, M Khamaisi, Z Abassi, SN Heyman |
Drug Safety | 2017 |
|
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
D Kawanami, K Matoba, Y Takeda, Y Nagai, T Akamine, T Yokota, K Sango, K Utsunomiya |
International journal of molecular sciences | 2017 |
|
Empagliflozin: a new strategy for nephroprotection in diabetes
AI Korbut, VV Klimontov |
Diabetes mellitus | 2017 |
|
Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects: NORTON et al
L Norton, CE Shannon, M Fourcaudot, C Hu, N Wang, W Ren, J Song, M Abdul-Ghani, RA DeFronzo, J Ren, W Jia |
Diabetes, obesity & metabolism | 2017 |
|
Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes: SOLINI et al
A Solini, C Rossi, CM Mazzanti, A Proietti, H Koepsell, E Ferrannini |
Diabetes, obesity & metabolism | 2017 |
|
Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus
J Mondick, M Riggs, S Kaspers, N Soleymanlou, J Marquard, V Nock |
Journal of clinical pharmacology | 2017 |
|
The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
O Steen, RM Goldenberg |
Canadian Journal of Diabetes | 2017 |
|
SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?
N Ahmed-Sarwar, AK Nagel, S Leistman, K Heacock |
The Annals of pharmacotherapy | 2017 |
|
WITHDRAWN: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
O Steen, RM Goldenberg |
Canadian Journal of Diabetes | 2017 |
|
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
V Vallon, SC Thomson |
Diabetologia | 2016 |
|
Sodium–glucose cotransporter 2 inhibition: cardioprotection by treating diabetes—a translational viewpoint explaining its potential salutary effects
AE de Leeuw, RA de Boer |
European Heart Journal - Cardiovascular Pharmacotherapy | 2016 |
|
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
LA Gallo, MS Ward, AK Fotheringham, A Zhuang, DJ Borg, NB Flemming, BM Harvie, TL Kinneally, SM Yeh, DA McCarthy, H Koepsell, V Vallon, C Pollock, U Panchapakesan, JM Forbes |
Scientific Reports | 2016 |
|
Pharmacological analysis of SGLT2 inhibitor (tofogliflozin) using in vivo glucose clamp and titration protocols in rats and cynomolgus monkeys
M Fukazawa, T Nagata, M Suzuki, Y Suzuki, Y Kawabe |
Folia Pharmacologica Japonica | 2016 |
|
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
RA DeFronzo, L Norton, M Abdul-Ghani |
Nature Reviews Nephrology | 2016 |
|
The renal effects of SGLT2 inhibitors and a mini-review of the literature
V Andrianesis, S Glykofridi, J Doupis |
Therapeutic Advances in Endocrinology and Metabolism | 2016 |
|
The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
MR Weir |
Postgraduate Medicine | 2016 |
|
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
CI Choi |
Molecules (Basel, Switzerland) | 2016 |
|
Suppressing hyperinsulinemia prevents obesity but causes rapid onset of diabetes in leptin-deficient Lepob/ob mice
AM D'souza, JD Johnson, SM Clee, TJ Kieffer |
Molecular Metabolism | 2016 |
|
Abordaje de la diabetes mellitus tipo 2 a través del cotransportador sodio-glucosa tipo 2: ¿tiene sentido?
J Segura |
Medicina Clínica | 2016 |
|
Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
F Zaccardi, DR Webb, T Yates, MJ Davies |
Postgraduate medical journal | 2015 |
|
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
V Vallon |
Annual Review of Medicine | 2015 |
|
Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes
V Valentine, D Hinnen |
Clinical diabetes : a publication of the American Diabetes Association | 2015 |
|
Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
K Yamada, H Nakayama, S Yoshinobu, S Kawano, M Tsuruta, M Nohara, R Hasuo, S Akasu, I Tokubuchi, N Wada, S Hirao, S Iwata, H Kaku, Y Tajiri |
Journal of Diabetes Investigation | 2015 |
|
Renal Sodium-Glucose Cotransporter Inhibition in the Management of Type 2 Diabetes Mellitus
MA Abdul-Ghani, L Norton, RA DeFronzo |
American journal of physiology. Renal physiology | 2015 |
|
Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
LA Gallo, EM Wright, V Vallon |
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease | 2015 |
|
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
P Fioretto, A Giaccari, G Sesti |
Cardiovascular Diabetology | 2015 |
|
International Textbook of Diabetes Mellitus: DeFronzo/International Textbook of Diabetes Mellitus, Fourth Edition
RN Bergman, M Ader |
International Textbook of Diabetes Mellitus: DeFronzo/International Textbook of Diabetes Mellitus, Fourth Edition | 2015 |
|
SGLT2 inhibitors
I Dardi, T Kouvatsos, SA Jabbour |
Biochemical Pharmacology | 2015 |
|
Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes
Y Nakamura, Y Nagai, Y Terashima, A Nishine, S Ishii, H Kato, A Ohta, Y Tanaka |
Expert Opinion on Pharmacotherapy | 2015 |
|
Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview
Juan F. Mosley II, Lillian Smith, Emily Everton, Chris Fellner |
Pharmacy and Therapeutics | 2015 |
|
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
J Rosenstock, E Ferrannini |
Diabetes care | 2015 |
|
The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes
PM Katz, LA Leiter |
Canadian Journal of Diabetes | 2015 |
|
Pharmacological and clinical profile of a novel SGLT2 inhibitor canagliflozin hydrate (CANAGLU®)
C Kuriyama, K Ueta, K Arakawa |
Folia Pharmacologica Japonica | 2015 |
|
Novel Agents for the Treatment of Type 2 Diabetes
RA DeFronzo, CL Triplitt, M Abdul-Ghani, E Cersosimo |
Diabetes spectrum : a publication of the American Diabetes Association | 2014 |
|
Impaired decline in renal threshold for glucose during pregnancy - a possible novel mechanism for gestational diabetes mellitus: High Renal Threshold for Glucose in GDM
P Klein, D Polidori, O Twito, A Jaffe |
Diabetes/Metabolism Research and Reviews | 2014 |
|
SGLT2 inhibitors in the treatment of type 2 diabetes
FM Hasan, M Alsahli, JE Gerich |
Diabetes Research and Clinical Practice | 2014 |
|
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
EM Lamos, LM Younk, SN Davis |
Expert Opinion on Investigational Drugs | 2014 |
|
Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
S Sha, D Devineni, A Ghosh, D Polidori, M Hompesch, S Arnolds, L Morrow, H Spitzer, K Demarest, P Rothenberg, NC Barengo |
PloS one | 2014 |
|
Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
B Haas, N Eckstein, V Pfeifer, P Mayer, MD Hass |
2014 | |
|
Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes
JA Davidson, L Kuritzky |
Postgraduate Medicine | 2014 |
|
SGLT2 Inhibitors to Control Glycemia in Type 2 Diabetes Mellitus: A New Approach to an Old Problem
SA Jabbour |
Postgraduate Medicine | 2014 |
|
The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
JP Wilding |
Metabolism | 2014 |
|
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control
EC Chao |
Clinical diabetes : a publication of the American Diabetes Association | 2014 |
|
Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease
G Vlotides, PR Mertens |
Nephrology Dialysis Transplantation | 2014 |
|
Sodium Glucose Cotransporter 2 Inhibitors
JR White |
2014 | |
|
SGLT-2 inhibition in patients with kidney disease
RE Gilbert |
2014 | |
|
Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport
MA Abdul-Ghani, RA DeFronzo |
Journal of Internal Medicine | 2014 |
|
Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin
T Kadokura, W Zhang, W Krauwinkel, S Leeflang, J Keirns, Y Taniuchi, I Nakajo, R Smulders |
Clinical Pharmacokinetics | 2014 |
|
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
JP Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel, G Meininger |
International journal of clinical practice. Supplement | 2013 |
|
Canagliflozin: a novel treatment option for type 2 diabetes
E Dietrich, J Powell, JR Taylor |
Drug design, development and therapy | 2013 |
|
Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
RR Poudel |
Indian journal of endocrinology and metabolism | 2013 |
|
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
E Ferrannini, SA Veltkamp, RA Smulders, T Kadokura |
Diabetes care | 2013 |
|
SGLT2 Inhibition: A Novel Prospective Strategy in Treatment of Diabetes Mellitus
AB Deshmukh, MC Patel, B Mishra |
Renal Failure | 2013 |
|
Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
E Kurosaki, H Ogasawara |
Pharmacology & Therapeutics | 2013 |
|
Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus: The Journal of Clinical Pharmacology
D Devineni, CR Curtin, D Polidori, MJ Gutierrez, J Murphy, S Rusch, PL Rothenberg |
The Journal of Clinical Pharmacology | 2013 |
|
Canagliflozin for the treatment of adults with Type 2 diabetes
PJ Aschner |
Diabetes Management | 2013 |
|
Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis: Role of SGLT2 in Tubular Apoptosis
S Maeda, T Matsui, M Takeuchi, S Yamagishi |
Diabetes/Metabolism Research and Reviews | 2013 |
|
SGLT2 inhibitors for diabetes: turning symptoms into therapy
M Diamant, LM Morsink |
The Lancet | 2013 |
|
Industrial natural product chemistry for drug discovery and development
A Bauer, M Brönstrup |
Natural Product Reports | 2013 |
|
Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans
Muhammad A Abdul-Ghani, Ralph A DeFronzo, Luke Norton |
2013 | |
|
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
Ralph A DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, Xiaoni Liu, Ying Hong, Marc Pfister, Linda A Morrow, Bruce R Leslie, David W Boulton, Agatha Ching, Frank P LaCreta, Steven C Griffen |
2013 | |
|
Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial
B Bode, K Stenlöf, D Sullivan, A Fung, K Usiskin |
Hospital Practice | 2013 |
|
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, Xiaoni Liu, Ying Hong, Marc Pfister, Linda A. Morrow, Bruce R. Leslie, David W. Boulton, Agatha Ching, Frank P. LaCreta, Steven C. Griffen |
2013 | |
|
Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
Muhammad A. Abdul-Ghani, Ralph A. DeFronzo, Luke Norton |
2013 | |
|
Dapagliflozin for the treatment of type 2 diabetes
MA Abdul-Ghani, RA DeFronzo |
Expert Opinion on Pharmacotherapy | 2013 |
|
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
E Ferrannini, A Solini |
Nature Reviews Endocrinology | 2012 |
|
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
MA Abdul-Ghani, L Norton, RA DeFronzo |
Current Diabetes Reports | 2012 |
|
Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?
J Liu, T Lee, RA DeFronzo |
2012 | |
|
Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
Y Liang, K Arakawa, K Ueta, Y Matsushita, C Kuriyama, T Martin, F Du, Y Liu, J Xu, B Conway, J Conway, D Polidori, K Ways, K Demarest, GP Fadini |
PloS one | 2012 |
|
Regulation of the human Na + -dependent glucose cotransporter hSGLT2
C Ghezzi, EM Wright |
American journal of physiology. Cell physiology | 2012 |
|
Antibodies in metabolic diseases
B Ahrens |
New Biotechnology | 2011 |
|
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
RA DeFronzo, JA Davidson, SD Prato |
Diabetes Obesity and Metabolism | 2011 |
|
Learning From Glycosuria
E Ferrannini |
2011 | |
|
A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition
J Basile |
Postgraduate Medicine | 2011 |
|
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
MA Abdul-Ghani, L Norton, RA DeFronzo |
Endocrine reviews | 2011 |
|
Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature
PA Carpino, B Goodwin |
Expert Opinion on Therapeutic Patents | 2010 |
|
SGLT2 inhibition — a novel strategy for diabetes treatment
EC Chao, RR Henry |
Nature Reviews Drug Discovery | 2010 |
|
Sodium-glucose transporter-2 inhibition as an antidiabetic therapy
E Ferrannini |
Nephrology Dialysis Transplantation | 2010 |
|
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
E Ferrannini, SJ Ramos, A Salsali, W Tang, JF List |
2010 | |
|
Glucose Control by the Kidney: An Emerging Target in Diabetes
O Marsenic |
American Journal of Kidney Diseases | 2009 |
|
Novartis Foundation Symposia
EJ Campbell |
Ciba Foundation Symposium 44 - Research and Medical Practice: Their Interaction | 2008 |
|
Diabetes Mellitus
MA Sperling, SA Weinzimer, WV Tamborlane |
Pediatric Endocrinology | 2008 |
|
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
JF List, V Woo, E Morales, W Tang, FT Fiedorek |
2008 | |
|
Biological Monitoring of Toxic Metals
TW Clarkson, L Friberg, GF Nordberg, PR Sager |
1988 | |
|
Enhancement of glomerular filtration rate and renal plasma flow by oral glucose load in well controlled insulin-dependent diabetics
JS Christiansen, CK Christensen, K Hermansen, EB Pedersen, CE Mogensen |
Scandinavian Journal of Clinical & Laboratory Investigation | 1986 |
|
Kinetic studies of d-glucose transport in renal brush-border membrane vesicles of streptozotocin-induced diabetic rats
ME Blank, F Bode, E Huland, DF Diedrich, K Baumann |
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research | 1985 |
|
Klinik der inneren Sekretion
A Labhart |
1978 | |
|
Diabetes mellitus • B
R Beckmann, M Berger, A Beringer, P Berchtold, J Beyer, A Bischoff, G Brehm, BF Clarke, GR Constam, LJ Duncan, FA Gries, A Hasselblatt, R Hild, K Irmscher, K Jahnke, J Kühnau, H Liebermeister, K Lundbaek, G Meyer-Schwickerath, S Napp-Mellinghoff, M Neubauer, F Nobbe, K Oberdisse, P Petrides, R Petzoldt, H Sauer, K Schöffling, M Spitznas, J Steinke, M Vogel, KH Vogelberg, A Wessing |
1977 | |
|
La glicosuria
S Marigo |
Acta Diabetologica Latina | 1974 |
|
THE GLOMERULAR FILTRATION RATE DURING MODERATE HYPERGLYCEMIA IN NORMAL MAN
J Brøchner-Mortensen |
Acta Medica Scandinavica | 1973 |
|
Zur Wirkung von Glucose und Insulin auf die renale Kaliumausscheidung der gesunden und insuffizienten Niere
H Ludwig, L Heuer |
Research in Experimental Medicine | 1972 |
|
Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic Subjects
CE Mogensen |
Scandinavian Journal of Clinical & Laboratory Investigation | 1971 |
|
Nierenkrankheiten
H Schwiegk, E Buchborn, K Čapek, P Deetjen, J Eigler, K Federlin, R Heintz, J Heller, H Jesserer, A Kleinschmidt, F Krück, J Martínek, EF Pfeiffer, R Richterich, G Riecker, K Thurau, F Wahlig, H Wirz, HU Zollinger |
1968 | |
|
Physiologie und Pathologische Physiologie / Physiology and Pathological Physiology / Physiologie Normale et Pathologique
B Fey, F Heni, A Kuntz, DF McDonald, L Quénu, LG Wesson, C Wilson |
1965 | |
|
Ergebnisse der Inneren Medizin und Kinderheilkunde
L Heilmeyer, R Schoen, B Rudder |
1960 | |
|
Managing Unmanageable Edema
EY Berger |
Postgraduate Medicine | 1959 |
|
Physiologic aspects of glomerulonephritis
SJ Farber |
Journal of Chronic Diseases | 1957 |
|
Renal glycosuria
L Horowitz, S Schwarzer |
The Journal of Pediatrics | 1955 |
|
The effect of insulin on the excretion of glucose and phosphate by the kidney of the cat
MG Eggleton, S Shuster |
The Journal of Physiology | 1954 |
|
Die Stellung der Niere im Kohlenhydratstoffwechsel
A Kleinschmidt |
Klinische Wochenschrift | 1953 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)